Edition:
United Kingdom

Jounce Therapeutics Inc (JNCE.OQ)

JNCE.OQ on NASDAQ Stock Exchange Global Select Market

7.27USD
20 Aug 2018
Change (% chg)

$-0.22 (-2.94%)
Prev Close
$7.49
Open
$7.49
Day's High
$7.50
Day's Low
$7.17
Volume
53,960
Avg. Vol
172,334
52-wk High
$29.02
52-wk Low
$6.56

Chart for

About

Jounce Therapeutics, Inc. is a clinical stage immunotherapy company. The Company is engaged in transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients. Through the use of its Translational Science Platform, Jounce first focuses on... (more)

Overall

Beta: --
Market Cap(Mil.): $554.71
Shares Outstanding(Mil.): 32.19
Dividend: --
Yield (%): --

Financials

  JNCE.OQ Industry Sector
P/E (TTM): 7,903.67 85.68 32.76
EPS (TTM): 0.00 -- --
ROI: 4.65 1.78 14.61
ROE: 0.82 3.28 16.33

BRIEF-Jounce Therapeutics Q1 Shr Loss $0.40

* JOUNCE THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

09 May 2018

BRIEF-Jounce Therapeutics Reports Q1 Loss Per Share Of $0.40

* JOUNCE THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

09 May 2018

BRIEF-Jounce Therapeutics Files For Mixed Shelf Of Up To $250 Mln

* JOUNCE THERAPEUTICS INC FILES FOR MIXED SHELF OF UP TO $250 MILLION - SEC FILING

08 Mar 2018

BRIEF-Jounce Therapeutics Q4 Loss Per Share $0.29

* JOUNCE THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

08 Mar 2018

Earnings vs. Estimates